Anti-IL-20 monoclonal antibody suppresses hepatocellular carcinoma progression

WEN-ZHOU DING1*, GUO-YONG HAN2*, HUI-HAN JIN1*, CHUAN-FEI ZHAN2, YUAN JI1 and XIN-LI HUANG3

1Department of Hepatobiliary Surgery, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi, Jiangsu 214002; 2Key Laboratory of Living Donor Liver Transplantation, National Health and Family Planning Commission, Department of Liver Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029; 3Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China

Received October 21, 2017; Accepted August 30, 2018

DOI: 10.3892/ol.2018.9402

Abstract. Interleukin (IL)-20 is a member of the IL-10 family of cytokines, which has been reported to participate in autoimmune inflammatory diseases. However, the potential role of IL-20 in hepatocellular carcinoma (HCC) progression has not yet been investigated. In the present study, it was observed that IL-20 mRNA and protein levels were markedly increased in the HCC tissues examined via reverse transcription-quantitative polymerase chain reaction and immunohistochemical staining. In addition, IL-20 expression was significantly associated with tumor size, metastasis, TNM stage and poor prognosis in patients with HCC. Mouse recombinant IL-20 (mIL-20) enhanced liver cancer cell proliferation, migration and invasion in vitro, while the anti-IL-20 monoclonal antibody (mAb) attenuated the effect of mIL-20, inhibiting cancer cell migration and invasion in vitro and suppressing cell growth in vitro and in vivo. This was detected by Cell Counting Kit-8, colony formation, Transwell assays and a xenograft tumor nude mouse model. Western blotting revealed that IL-20 promoted HCC progression through inducing transforming growth factor-β and matrix metalloproteinase 9 expression and enhancing the phosphorylation of Jun N-terminal kinase and signal transducer and activator of transcription 3. The results of the present study indicated that IL-20 promotes HCC development. In addition, anti-IL-20 mAb may attenuate the effect of IL-20 and suppress liver tumorigenesis in vitro and in vivo, indicating that anti-IL-20 mAbs may potentially serve as effective therapeutic agents for HCC.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancer types worldwide and the third leading cause of tumor-related deaths (1,2). While significant progress has been achieved in surgical resection, liver transplantation and interventional therapy in recent years, the overall survival of patients with HCC remains unsatisfactory due to late diagnosis, early metastasis and a high rate of recurrence. Therefore, clarification of the mechanisms underlying HCC progression is essential to developing effective therapeutic strategies.

Interleukin (IL) 20 is a member of the IL-10 family of cytokines, which includes IL-10, IL-19, IL-22, IL-24 and IL-26 (3,4). IL-20 shares 18-25% amino acid sequence identity with IL-10 (5). IL-20 acts by activating a heterodimer receptor complex of IL-20 receptor A/IL-20 receptor B (IL-20RA/IL-20RB) or IL-22 receptor A/IL-20 receptor B (IL-22RA/IL-20RB) (6). Earlier studies have reported a close association of IL-20 with inflammatory diseases, such as psoriasis, rheumatoid arthritis and atherosclerosis (7,8), and more recent investigations suggested an important role of IL-20 in tumor progression. Hsu et al (9), demonstrated that IL-20 accelerates breast cancer cell proliferation and migration, and enhances tumor progression through upregulating matrix metalloproteinase (MMP)-9, MMP-12, cathepsin K and cathepsin G. Moreover, the anti-IL-20 monoclonal antibody (mAb) 7E suppressed breast tumor growth in vivo. In bladder cancer, IL-20 was shown to promote cell migration and invasion via ERK1/2-dependent MMP-9 expression, and knockdown of IL-20R1 induced significant suppression of migration, invasion, ERK1/2 activation and NF-kB-mediated MMP-9 expression induced by IL-20 (10).

The liver is a potential target organ for IL-19, IL-20 and IL-24. IL-20 induces rapid tyrosine phosphorylation of the signal transducer and activator of transcription 3 (STAT3) by interacting with IL-20R heterodimers (type I or type II). In a previous study, STAT3 phosphorylation was enhanced upon treatment of cultured murine hepatocytes with IL-20 (11). IL-20 expression was significantly associated with tumor size, metastasis, TNM stage and poor prognosis in patients with HCC. Mouse recombinant IL-20 (mIL-20) enhanced liver cancer cell proliferation, migration and invasion in vitro, while the anti-IL-20 monoclonal antibody (mAb) 7E suppressed breast tumor growth in vivo. This was detected by Cell Counting Kit-8, colony formation, Transwell assays and a xenograft tumor nude mouse model. Western blotting revealed that IL-20 promoted HCC progression through inducing transforming growth factor-β and matrix metalloproteinase 9 expression and enhancing the phosphorylation of Jun N-terminal kinase and signal transducer and activator of transcription 3. The results of the present study indicated that IL-20 promotes HCC development. In addition, anti-IL-20 mAb may attenuate the effect of IL-20 and suppress liver tumorigenesis in vitro and in vivo, indicating that anti-IL-20 mAbs may potentially serve as effective therapeutic agents for HCC.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancer types worldwide and the third leading cause of tumor-related deaths (1,2). While significant progress has been achieved in surgical resection, liver transplantation and interventional therapy in recent years, the overall survival of patients with HCC remains unsatisfactory due to late diagnosis, early metastasis and a high rate of recurrence. Therefore, clarification of the mechanisms underlying HCC progression is essential to developing effective therapeutic strategies.

Interleukin (IL) 20 is a member of the IL-10 family of cytokines, which includes IL-10, IL-19, IL-22, IL-24 and IL-26 (3,4). IL-20 shares 18-25% amino acid sequence identity with IL-10 (5). IL-20 acts by activating a heterodimer receptor complex of IL-20 receptor A/IL-20 receptor B (IL-20RA/IL-20RB) or IL-22 receptor A/IL-20 receptor B (IL-22RA/IL-20RB) (6). Earlier studies have reported a close association of IL-20 with inflammatory diseases, such as psoriasis, rheumatoid arthritis and atherosclerosis (7,8), and more recent investigations suggested an important role of IL-20 in tumor progression. Hsu et al (9), demonstrated that IL-20 accelerates breast cancer cell proliferation and migration, and enhances tumor progression through upregulating matrix metalloproteinase (MMP)-9, MMP-12, cathepsin K and cathepsin G. Moreover, the anti-IL-20 monoclonal antibody (mAb) 7E suppressed breast tumor growth in vivo. In bladder cancer, IL-20 was shown to promote cell migration and invasion via ERK1/2-dependent MMP-9 expression, and knockdown of IL-20R1 induced significant suppression of migration, invasion, ERK1/2 activation and NF-kB-mediated MMP-9 expression induced by IL-20 (10).

The liver is a potential target organ for IL-19, IL-20 and IL-24. IL-20 induces rapid tyrosine phosphorylation of the signal transducer and activator of transcription 3 (STAT3) by interacting with IL-20R heterodimers (type I or type II). In a previous study, STAT3 phosphorylation was enhanced upon treatment of cultured murine hepatocytes with IL-20 (11). IL-20
is highly expressed in liver tissue under conditions of injury, such as fibrosis, cirrhosis and HCC. IL-20 activates hepatic stellate cells, upregulates TGF-β1 expression and promotes the occurrence and progression of liver fibrosis. mAbs against IL-20 or IL-20R can attenuate hepatocyte damage caused by CCl4 and protect IL-20R1-deficient mice from short-term and long-term liver injury (12). These collective findings clearly support the involvement of IL-20 in liver disease progression. However, the specific functions and mechanisms of action of IL-20 in HCC require further exploration.

Materials and methods

Tissue specimens. Tumor tissue samples were obtained from 64 patients with HCC. Adjacent non-tumorous tissues were obtained from 2 cm away from the edge of the tumors. All patients underwent curative resection of HCC at the First Affiliated Hospital of Nanjing Medical University (Nanjing, China) between December 2010 and January 2012. The tissue samples were confirmed by pathological examination and immediately stored in liquid nitrogen after surgery. Written informed consent was obtained from individual patients prior to surgery. The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University.

Cell lines and cultures. The mouse liver cancer cell line Hep-6 was purchased from the Chinese Academy of Sciences Cell Bank (Shanghai, China). Cells were cultured in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and 100 units/ml penicillin-streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.), and maintained at 37˚C in a humidified incubator with 5% CO2.

RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). TRIzol reagent (Takara Biotechnology Co., Ltd., Dalian, China) was used, according to the manufacturer’s protocol, to extract total RNA. The quality and concentration of RNA was determined using a Nanodrop™ 2000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.). RT-qPCR was performed using SYBR Premix ExTaq (Takara Biotechnology, Co., Ltd.) with the ABI Prism 7900 HT Thermocycler (Applied Biosystems; Thermo Fisher Scientific, Inc.) and maintained at 37˚C in a humidified incubator with 5% CO2.

Immunohistochemical staining. All tissues were paraffin-embedded and obtained from the Department of Pathology of The First Affiliated Hospital of Nanjing Medical University. Paraffin-embedded tissues were cut into 4-µm thick sections, and incubated with the rabbit anti-IL-20 polyclonal antibody (dilution, 1:100; LifeSpan BioSciences, Inc., Seattle, WA, USA) overnight at 4˚C. SP-9000 Histostain™-Plus kits (ZSGB-Bio, Beijing, China) were used according to the manufacturer’s protocols. Scoring was determined according to the intensity of staining in the cell cytoplasm: 0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining.

Cell proliferation assay. Hep-6 cells were seeded into 96-well plates at 100 µl complete medium, at a density of 2,000-5,000 cells/well. Mouse recombinant IL-20 (mIL-20) (300 ng/ml; R&D Systems), anti-IL-20 mAb (3 mg/ml) or mIL-20 plus anti-IL-20 mAb (dilution, 1:10) was added to the culture system. A Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was used, according to the manufacturer's instructions, to measure the cell viability. Each experiment was repeated at least three times.

Western blot analysis. Specimens were lysed on ice in lysis buffer 50 mM Tris-Cl pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 1% ethyl phenyl polyethylene glycol, 0.1% sodium dodecyl sulfate (SDS), 1 mM ethylenediaminetetraacetic acid (EDTA), 100 mM NaF, 1 mM Na3VO4, 1 mM phenylmethanesulfonyl fluoride (PMSF), and 2 µg/ml aprotinin, and the total protein contents were determined with the Bradford method. Protein samples (20 µg) were separated via 10% SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% bull serum albumin in Tris-buffered saline with Tween (TBST) at room temperature for 2 h, and then incubated with primary antibodies overnight at 4˚C. After washing with TBST three times for 15 min each, the membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies for 2 h at room temperature. TBST wash steps were performed as described previously, and proteins were visualized using an enhanced chemiluminescence detection kit according to the manufacturer’s recommendations (Beyotime Institute of Biotechnology, Haimen, China). Primary antibodies used in the present study included the following: Rabbit anti-IL-20 mAb (dilution, 1:150; R&D Systems, Inc., Minneapolis, MN, USA), rabbit anti-MMP-9 polyclonal antibody (dilution, 1:1,000; Abcam, Cambridge, MA, USA), rabbit anti-p-STAT3 polyclonal antibody (dilution, 1:1,000), rabbit anti-p-JNK polyclonal antibody (dilution, 1:1,000), rabbit anti-β-actin polyclonal antibody (dilution, 1:1,000), and rabbit anti-GAPDH polyclonal antibody (dilution, 1:1,000) (all from Cell Signaling Technology, Inc., Danvers, MA, USA). The protein levels were calculated relative to the level of GAPDH.
Cell migration and invasion assays. The migration and invasion assays were performed using Transwell chambers (Corning Incorporated, Corning, NY, USA) with 8-µm pore size. For the migration assay, 2x10^4 cells in 250 µl RPMI-1640 medium containing 0.2% FBS were seeded into the upper chamber of each well. mIL-20 (300 ng/ml), anti-IL-20 mAb (3 mg/ml) or mIL-20 plus anti-IL-20 mAb (1:10) was added to the upper chambers. The lower chambers were filled with 500 µl RPMI-1640 medium containing 10% FBS. Cells were incubated in 5% CO₂ at 37°C for 24 h. Subsequently, the cells on the upper surface of the chamber were removed using a cotton tip, and the wells were fixed in methanol for 20 min, then crystal violet was used to stain the migrated cells. Images from five random fields were captured for quantification and analysis. Three identical replicates were tested. For invasion, the upper chambers were coated with 100 µl Matrigel (dilution, 1:8; BD Biosciences, Franklin Lakes, NJ, USA) prior to seeding of the cells. The other steps were the same as for the migration assay.

In vivo tumorigenicity assay. Male nude mice, aged 4-6 weeks, were housed under specific pathogen-free conditions and cared for according to the institutional guidelines for animal care. All animal experiments met the National Institutes of Health guidelines and were approved by the Committee on the Ethics of Animal Experiments of Nanjing Medical University. In total, 5x10^5 cells were injected subcutaneously into the opposite inguinal in the same mice. Animals were randomly assigned to three groups (n=3 per group) and treated with PBS, membrane immunoglobulin G (mIgG) or anti-IL-20 mAb (5 mg/kg; subcutaneous injection) every 5 days for the duration of the experiment. Mice were monitored every 5 days and sacrificed 35 days after injection. Tumor sizes, weights and volumes were determined for further analysis. Levels of related proteins were examined via western blotting, according to the aforementioned protocols.

Statistical analyses. Statistical analyses were performed using GraphPad Prism v.5.0 (GraphPad Software, La Jolla, CA, USA) software and SPSS v.18.0 (SPSS, Inc., Chicago, IL, USA). Quantitative data were presented as the mean ± standard error of mean. Differences between two groups were evaluated using the two-tailed Student’s t-test. The chi-square test was applied to analyze the clinical parameters. Kaplan-Meier analysis was applied to evaluate the prognosis. One-way analysis of variance with a non-parametric Kruskal-Wallis test were applied to analyze the clinical parameters. Kaplan-Meier analysis was applied to evaluate the association between IL-20 expression and patient age, patient sex or α-fetoprotein level. Kaplan-Meier analysis was applied to evaluate the association between IL-20 expression and prognosis. Notably, patients with high IL-20 expression had poorer overall survival than those with low IL-20 expression (P<0.01; Fig. 1C). Based on these findings, we hypothesize that IL-20 expression is frequently upregulated in HCC tissues and is associated with poor patient survival.

Expression of IL-20 is significantly associated with poor prognosis in patients with HCC. We collected data from 64 patients with HCC and examined the associations of clinical parameters with IL-20 expression patterns. As shown in Table I, IL-20 expression was strongly associated with adverse clinicopathological prognosticators, such as liver cirrhosis (P=0.0134), tumor size (P=0.0013), vascular invasion (P=0.0182) and TNM stage (P=0.0332). However, we observed no significant correlations between IL-20 expression and patient age, patient sex or α-fetoprotein level. Kaplan-Meier analysis was applied to evaluate the association between IL-20 expression and prognosis. Notably, patients with high IL-20 expression had poorer overall survival than those with low IL-20 expression (P<0.01; Fig. 1C). Based on these findings, we hypothesize that IL-20 expression is frequently upregulated in HCC tissues and is associated with poor patient survival.

Anti-IL-20 mAb inhibits proliferation and colony formation of HepG2 cells. To clarify the precise role of anti-IL-20 mAb in liver tumor cell growth, mIL-20, anti-IL-20 mAb, mIL-20 plus anti-IL-20 mAb or PBS (control) were added into the cell culture medium. As shown by the CCK-8 assays (Fig. 2A), compared

### Table I. Patient characteristics.

<table>
<thead>
<tr>
<th>Variables</th>
<th>IL-20 high (n)</th>
<th>IL-20 low (n)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥55</td>
<td>20</td>
<td>15</td>
<td>0.4792</td>
</tr>
<tr>
<td>&lt;55</td>
<td>14</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>23</td>
<td>16</td>
<td>0.2415</td>
</tr>
<tr>
<td>Female</td>
<td>11</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>AFP (ng/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥400</td>
<td>19</td>
<td>12</td>
<td>0.2045</td>
</tr>
<tr>
<td>&lt;400</td>
<td>15</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Liver cirrhosis</td>
<td>Yes</td>
<td>27</td>
<td>15</td>
</tr>
<tr>
<td>No</td>
<td>7</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥5</td>
<td>25</td>
<td>10</td>
<td>0.0013</td>
</tr>
<tr>
<td>&lt;5</td>
<td>9</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Vascular invasion</td>
<td>Yes</td>
<td>19</td>
<td>8</td>
</tr>
<tr>
<td>No</td>
<td>15</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>6</td>
<td>14</td>
<td>0.0332</td>
</tr>
<tr>
<td>III-IV</td>
<td>28</td>
<td>20</td>
<td></td>
</tr>
</tbody>
</table>

IL, interleukin; TNM, tumor-node-metastasis; AFP, α-fetoprotein.
with the control group, mIL-20 promoted cell proliferation (P<0.01), whereas anti-IL-20 mAb attenuated the effect of mIL-20 (P>0.05 vs. control), and inhibited Hep1-6 cell proliferation when applied alone (P<0.05 vs. control). As shown in Fig. 2B, colony formation in the presence of mIL-20 was significantly higher than that in the control group (P<0.01), while colony formation in the anti-IL-20 mAb group was inhibited (P<0.05 vs. control). Furthermore, the effect of mIL-20 was counteracted by the anti-IL-20 specific mAb (P>0.05 vs. control).

Anti-IL-20 mAb impairs the invasion and migration of Hep1-6 cells. Transwell chamber assays were employed to evaluate the invasive and migratory abilities of Hep1-6 cells treated with mIL-20, anti-IL-20 mAb, mIL-20 plus anti-IL-20 mAb,
or PBS. As shown in Fig. 2C and D, mIL-20 significantly enhanced Hep1-6 cell migration and invasion (both P<0.01 vs. control), and this effect was attenuated by the anti-IL-20 mAb (P>0.05 vs. control). Meanwhile, anti-IL-20 mAb suppressed Hep1-6 cell migration and invasion compared with the control group (P<0.05).

**IL-20 regulates HCC progression-related proteins in Hep1-6 cells.** To determine the mechanisms underlying the IL-20-mediated promotion of tumor development, we further examined its effects on molecules related to cancer progression. As shown in Fig. 3, the levels of TGF-β and MMP-9 were upregulated in cells to which mIL-20 had been added (Fig. 3A and C), as compared with in the control group. Moreover, phosphorylation of JNK and STAT3 was enhanced (Fig. 3B and D). These results clearly demonstrated the effects of IL-20 on factors related to HCC progression.

**Blocking IL-20 with the anti-IL-20 mAb inhibits tumor growth in vivo.** Considering that antibody-mediated regulation of IL-20 influenced Hep1-6 cell properties in vitro, we further analyzed whether this effect was reproducible in vivo. Overall, the tumor
sizes and weights in the experimental group (anti-IL-20 mAb treatment) were decreased compared with those in the control group (Fig. 4A-C). Western blot data revealed that TGF-β and MMP-9 expression, as well as the phosphorylation of STAT3 and JNK, were attenuated in the mAb-treated group (Fig. 4D-F). The collective findings indicate that the anti-IL-20 mAb effectively inhibits liver cancer cell growth, both in vivo and in vitro.

Discussion

IL-20, a member of the IL-10 family of cytokines, has been studied in various immunopathological diseases, including psoriasis, inflammatory bowel disease and rheumatoid arthritis (4). Recent studies have shown that IL-20 participates in tumor progression (9,10), and is also involved in liver injury, including fibrosis and short- and long-term liver injury (12). However, the role of IL-20 in HCC is still unknown.

In the present study, we investigated the expression patterns of IL-20 and its associations with the clinicopathological characteristics of patients with HCC. The data revealed overexpression of IL-20 in liver cancer tissues. Moreover, high intratumoral IL-20 expression was significantly associated with tumor size, vessel invasion, advanced TNM stage and poor prognosis. When added into the cell culture medium, mIL-20 promoted the growth, migration and invasion of liver cancer cells in vitro, while the anti-IL-20 mAb neutralized the effect of mIL-20 in vitro, and further suppressed liver tumorigenesis in a nude mouse tumor xenograft model.

Abnormal cell proliferation and metastasis has been recognized as an important factor for tumorigenesis and cancer-related mortality (14). To further determine the mechanism underlying IL-20-induced proliferation and metastasis, expression patterns of growth, migration and invasion-related molecules were examined in Hep1-6 cells cultured under different conditions. Western blot analysis showed that IL-20 enhanced the expression of TGF-β and MMP-9, as well as the activation of STAT3 and JNK. The anti-IL-20 mAb exerted the opposite effect, which was further verified by the in vivo data from subcutaneous tumors.

STAT3, JNK, TGF-β and MMP-9 have been established as participants in liver tumor progression (15-17). Phosphorylated STAT3 is detected in ~60% of human HCC tissues, with STAT3-positive tumors being more aggressive than STAT3-negative tumors (18). Approximately 70% of HCC tissues show positive immunostaining for phosphorylated JNK (19). JNKs are protein kinases that phosphorylate c-Jun at serine residues. c-Jun is a well-characterized oncogene, especially in liver, and its phosphorylation plays a critical role in HCC development (20,21). TGF-β, when activated, targets Snail and MMP-9 to promote tumor cell invasion and migration through the epithelial-mesenchymal transition (22). Our results were consistent with these earlier findings, supporting the theory that IL-20 promotes HCC progression through regulation of TGF-β, MMP-9, STAT3 and JNK. However, the specific molecular mechanisms of this regulation are unknown. Additionally, the expression patterns and roles of IL-20 receptors in HCC are still unclear and require further exploration in future studies.

In conclusion, we have demonstrated for the first time that IL-20 is overexpressed in human HCC and represents a promising prognostic predictor. IL-20 promotes liver cancer growth and metastasis through enhancing the expression of TGF-β and MMP-9, as well as the phosphorylation of STAT3 and JNK. Use of an anti-IL-20 mAb can attenuate the effects of IL-20 and effectively suppress HCC progression, both in vitro and in vivo. IL-20-specific antagonists may thus serve as potential therapeutic agents in HCC.

Acknowledgements

Not applicable.

Funding

The present study was supported by a grant from the Six Talent Peaks Project in Jiangsu Province (grant no. 2014-WSW-005).

Availability of data and materials

All data generated and/or analyzed during the present study are included in this published article.

Authors’ contributions

XH, WD, GH and HJ conceived the study. WD, GH and HJ designed and performed the experiments. CZ contributed to the performance of the experiments. YJ collected the clinical samples and performed the cell culture. WD wrote the manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from all patients prior to their inclusion to the study. The present study was approved by the Ethics Committee of The First Affiliated Hospital of Nanjing Medical University (Jiangsu, China).

Patient consent for publication

Written informed consent was obtained from all patients for the publication of their data.

Competing interests

The authors declare that they have no competing interests.

References


